Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Low volume pull back , reload when ever the bottom hits . Missed on earnings . We’ll see
https://viavid.webcasts.com/viewer/event.jsp?ei=1654785&tp_key=326a4f2402
Could go either way
Pull back to cover shorts complete , 2023 and first q financials should be release on 3/19 after hours . Of it sucks then it’ll tumble if not - 10$-15$ with in 6 months IMO
Grab some cheap ones -Shorts scrambling to get out should get interesting this week , gotta burn .75 or 1 mill at least before she starts going up imo
3 officers bought 500k worth of stock on 2/2/24 at 3.96 - been moving since
Schedule 13G filed at 4:44PM- Black Rock has now acquired over 5% of the o/s.
We are close to the big one! This also explains why the takedown has been so savage and successful- the largest firms in the world are loading up before we push to $100.
-$
This is a buy, imo they're about to announce positive results of Phase 1 abuse potential.
Grossly oversold right now, this is a $50B+ drug.
-$
NEWS -- Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that the first patient has been enrolled in the first Phase 3 clinical trial (RELIANCE I) for the Company's lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder (MDD).
"The initiation of our Phase 3 program for REL-1017 represents a significant operational milestone for our company," said Sergio Traversa, CEO of Relmada Therapeutics. "Importantly, the design of the Phase 3 program incorporates valuable guidance from the U.S. Food and Drug Administration (FDA) obtained in our successfully completed End-of-Phase 2 meeting. We believe that the reported positive Phase 2 results are indicative of the potential of REL-1017 to treat patients suffering from MDD. We look forward to the availability of top-line results from RELIANCE I in the first half of 2022."
"A significant unmet medical need continues to exist for therapeutics that demonstrate a rapid and robust antidepressant effect in patients with MDD, especially for patients who do not respond adequately to their first line of treatment. We are hopeful for the results of the RELIANCE trials and that in the near future physicians will have access to this novel treatment in their armamentarium " said Maurizio Fava, M.D., Chief of the Department of Psychiatry at Massachusetts General Hospital, and Principal Investigator for the REL-1017 Phase 3 program. "This important Phase 3 program provides us with an opportunity to confirm and further show the effect of REL-1017 in the treatment of MDD, a devastating and life altering condition with many sequelae. I am inspired and excited to continue evaluating this promising product candidate in late-stage clinical trials" said Marco Pappagallo, M.D. acting Chief Medical Officer of Relmada Therapeutics.
Key points of the Phase 3 program agreed upon in discussions with FDA include:
NEWS -- Relmada Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
Jefferies London Healthcare Conference
Date: Thursday, November 19, 2020
Time: 10:50 AM EST/3:50 PM GMT
Webcast: A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: HTTP://www.relmada.com. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
Piper Sandler 32nd Annual Healthcare Conference
Management will participate in a fireside chat, which will be accessible beginning on November 23, 2020, via the "Investors" section of the company's website: HTTP://www.relmada.com. The link will remain active for 90 days thereafter.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage pharmaceutical company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, and is entering late-stage studies as an adjunctive treatment for MDD in adults.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com
Media Inquiries:
FischTank PR
mailto://relmada@fischtankpr.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-upcoming-investor-conferences-301174575.html
SOURCE Relmada Therapeutics, Inc.
From the recent quarterly filing
NEWS -- Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the expansion of its leadership team with the appointments of Paolo Manfredi, M.D., as Acting Chief Scientific Officer and Marco Pappagallo, M.D., as Acting Chief Medical Officer. The Company also provided an update of upcoming milestones for the REL-1017 program.
Dr. Manfredi has been the co-founder of Medeor, Inc. (now merged into Relmada), for which he also served as Scientific Director and co-inventor of REL-1017. Prior to this, Dr. Manfredi was an Assistant Professor in Neurology and Neuroscience at the Weill Medical College of Cornell University and served as the Fellowship Director of the Pain and Palliative Care Program at Memorial Sloan Kettering Cancer Center. Dr. Manfredi earned his Doctor of Medicine at the University of Genoa, Italy, completed his residency in neurology at Albert Einstein College of Medicine and completed several postdoctoral training fellowships, including a pain management fellowship at Massachusetts General Hospital and Harvard University.
Dr. Pappagallo most recently served as Chief Medical Officer at CerSci Therapeutics, a privately-held biotech company focused on developing pain therapeutics that was recently acquired by ACADIA Pharmaceuticals. Prior to this, he held the role of Medical Expert-in-Residence and Executive Director of Medical Intelligence at Grünenthal - USA. Dr. Pappagallo previously served as the co-founder and Chief Medical Officer of NovaPharm Therapeutics. Dr. Pappagallo served in a number of senior roles at leading medical institutions, including as the Director of Chronic Pain in the Department of Pain and Palliative Care at Beth Israel Medical Center and Professor and Director of Pain Research in the Department of Anesthesiology at Mount Sinai Medical Center. Dr. Pappagallo completed his medical school and post-graduate training in neurosurgery at the University of Rome, Italy. Subsequently, he completed his neurology residency training at the State University of New York at Stony Brook and was a clinical and research fellow in pain medicine at John Hopkins University.
Relmada also provided an R&D milestone update, as the company continues to be on track to start its first pivotal Phase III trial of REL-1017 for the adjunctive treatment of major depressive disorder (MDD) in the fourth quarter of 2020. Also, this quarter, the company expects to begin its human abuse potential studies of REL-1017. Other anticipated milestones for REL-1017 in 2021 include:
Huge uptick block at the close
RLMD about to surface $40 next stop then 48 quickly
Needed the close above 35.25 today
Jeffries reiterates buy w target of $75 ( $175 potentially)
https://javatar.bluematrix.com/sellside/EmailDocViewer?encrypt=b56fc968-08b0-4333-8db0-68a8e28cc8ee&mime=html&co=Jefferies&id=robert.dicristina@theupsidegroup.com&source=mail
Decisive Day: broke 200 day MAV
Possibly drop to 34-35 support
https://stockcharts.com/h-sc/ui?s=RLMD
Expected RLMD to drop to 36-37 (it hit 38.5) but bounced to 43.
A close above 45.5 would repair the chart trend.
https://stockcharts.com/h-sc/ui?s=RLMD
The chart seems to show it could drop again but I’m not selling,
Oppenheimer just issued a buy w price target of $75. All 5 reports indicate the revenues from their drug will be 1b + within a few years. Fibonacci indicates 71 after closing above 50.
I’ve predicted it will hit $500 soon after REL-1017 is approved and sales begin. It’s the safest, cheapest and fastest acting drug for depression yet developed. Missed my July 4th target. BTD would help.
I’m riding this like Ahab rode Moby Dick but hoping for a better ending.
NEWS -- Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
NEW YORK, July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "RLMD."
The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com
For Media Inquiries:
FischTank PR
mailto://relmada@fischtankpr.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-uplisting-to-the-nasdaq-global-select-market-301092149.html
SOURCE Relmada Therapeutics, Inc.
selling 10% at $100 this year, 10% at $150 next year then buying puts just before the phase 3 results are released, kissing that put $ goodbye and selling the balance at $3,000 in 4 years ( based on Goldman’s and others revenue estimates)
Good close just above the 50 day moving average, repairing the chart pattern
Relmada on Russell 3000 and 2000 indexes
Causing 1.5mm+ shares TO BE put away for at least a year
25% move on BTD
Strange day
‘Always expect the unexpected’ —Roald Dahl
1.5mm shares + crossed and put away in the Russell 2000 and 3000 funds
Market didn’t help, a delicate transaction. Jeffries probably queried all large holders seeking any weak hands for the cross....it’s a good thing, shares out of the float for at least a year.
AXSM got a nice boost from Breakthrough Therapy Designation....
NEWS -- Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
Patent Further Expands Company's Intellectual Property Protection for REL-1017 a Novel NMDA Receptor Antagonist, in a Major Global Market
NEW YORK , June 23, 2020 /CNW/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the receipt of a Notice of Allowance from the Canadian Intellectual Property Office for Relmada's patent application number, 2,893,238, titled, "d-Methadone for the Treatment of Psychiatric Symptoms." The patent that will issue from this allowed application provides broad coverage in Canada for REL-1017 (d-methadone, dextromethadone,), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of symptoms associated with a wide range of psychological and psychiatric disorders, including depression, anxiety, fatigue, and mood instability.
"This patent, which has previously been granted in the U.S., EU, Australia , China , Hong Kong , Mexico , and South Korea , advances our objective of further strengthening our intellectual property portfolio in multiple key markets around the world," said Sergio Traversa , CEO of Relmada Therapeutics. " Canada represents a significant market opportunity for Relmada, as published research indicates that the 12 months' prevalence rate of major depressive disorder (MDD) in Canada was 4.7%, and the lifetime prevalence rate was 11.2%¹. We look forward to initiating our Phase 3 program for REL-1017 for the adjunctive treatment of MDD in the fourth quarter of this year."
Relmada recently completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on its development program of REL-1017 for the adjunctive treatment of MDD patients. Based on the FDA feedback, the Company can proceed into Phase 3 without conducting additional clinical studies, and the FDA and Relmada are aligned on all key aspects of the planned Phase 3 program.
About REL-1017 (dextromethadone)
REL-1017 is a non-competitive N-methyl-D-aspartate Receptor (NMDAR) antagonist with the potential to be the first oral single agent NMDAR antagonist approved for the adjunctive treatment of MDD. In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo on efficacy measures. The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017 , the FDA granted Fast Track designation for dextromethadone for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com
For Media Inquiries:
FischTank PR
mailto://relmada@fischtankpr.com
¹ Knoll, A. D., & MacLennan, R. N. (2017). Prevalence and correlates of depression in Canada : Findings from the Canadian Community Health Survey. Canadian Psychology/Psychologie Canadienne, 58(2), 116–123.
View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-notice-of-allowance-for-patent-in-canada-covering-rel-1017-for-treatment-of-psychiatric-symptoms-301081913.html
SOURCE Relmada Therapeutics, Inc.
Notes from recent presentations
In the GS event the question was asked about how do Phase 2 results get duplicated in the critical Phase 3 trials.
Sergio Traversa answers: Good question, can distill it down to two reasons why there is a depression trial fail,
one is the patient selection
and the other is the placebo effect
Why Relmada did well in Phase 2:
First half of test was in clinic, good control of placebo
Relmada uses two diagnostic tools in patient selection:
one is the SAFER test
Link to Safer pdf which helps to reduce the effect of having patients who are not really depressed but may have other CNS disorders.
Placebo effect is actually higher in clinic settings than in outside (at home) settings.
Upon the hiring of Marc de Somer MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety...
he outlined his goals at Relmada...
Former FDA CRO said recently ‘judging from the quality of the people they’re hiring RLMD looks like they are playing the long game’ meaning they are gearing up to take REL 1017 to approval not selling out
RTW Investments filed 13G showing additional 271.13K shares of RLMD purchased. Brings them up to 1.26M 8.26%
NEWS -- Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
NEW YORK, June 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.
Fireside Chat Details:
In the Russell 3000, waiting on 2000
register for live Jeffries Relmada presentation today at 10 Central
http://wsw.com/webcast/jeff126/register.aspx?conf=jeff126&page=rlmd&url=http://wsw.com/webcast/jeff126/rlmd/index.aspx
Use any company name
Rebroadcast available
Ask them.
Top notch people coming on board now. Dr. V served the company well and remains a stockholder
The change in team members
Wish we could get some scoop on why the change of team members
Specifically the change out of Dr. Ottavio Vitolo
This from the 2017 PR upon his joining the team...
Probably done at a much higher price
‘$100 by July 4th’
Good planning
Avoro Buys 7.7% of RLMD 13 F filed yesterday
https://avorocapital.com/
Jeffries announced a $75mm market offering
https://ih.advfn.com/stock-market/NASDAQ/relmada-therapeutics-RLMD/stock-news/82474251/prospectus-filed-pursuant-to-rule-424b5-424b5
after the close today the announcement about RLMD being added to the Russell indexes should be released. Best estimate I’ve seen is that would require the funds to add approximately 1.5mm shares sometime in June. With < 20mm AIO today and 70% closely held it should be... positive
Sun Trust Robinson Humphries initiates coverage w a buy target price $75
The Bible says you only need 3 witnesses to prove truth, we’ve got 4
If it doesn’t close above 40 it’s the overall market or some delay at FDA, expected.
NEWS -- Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
NEW YORK, April 28, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs. Dr. Walter will provide oversight for all U.S. and international regulatory strategy and operations. He has more than 30 years of experience in the biopharmaceutical industry, including 20 years in global regulatory affairs leading small molecule products and biologics, including antibodies and gene therapies, through the regulatory process from early development to approval.
Dr. Walter joins Relmada from REGENXBIO Inc., where he most recently served as Vice President of Regulatory Affairs, responsible for the global regulatory strategy, operations, pharmacovigilance, and medical writing for the company's portfolio of AAV-based gene therapy development candidates. Previously, from 2014 to 2018, Dr. Walter was Executive Director of Regulatory Affairs at Regeneron Pharmaceuticals, where he led and managed the regulatory affair liaison group for metabolic & endocrine, infectious diseases, immunology, drug-device combinations, and companion diagnostics for development and marketed products. From 2006 to 2014, Dr. Walter was Vice President, Regulatory Affairs, for Acorda Therapeutics, where he established and led the regulatory affairs department from pre-IPO to approval of the company's first marketed product. From 1994 to 2006, Dr. Walter served in multiple roles at Boehringer Ingelheim Pharmaceuticals, most recently as Senior Associate Director, Drug Regulatory Affairs, Cardiovascular, CNS and General Drugs Section. From 1989 to 1994, he was Group Head, Human Metabolism, Clinical Pharmacokinetics and Disposition Department, at CIBA-GEIGY Corporation. From 1988 to 1989, Dr. Walter was a chemist in the Biochemistry Department of BAYER Corporation, Agricultural division.
Dr. Walter earned his B.S. in biology from Denison University in Granville, Ohio, and his Ph.D. in toxicology and drug metabolism from the University of Kentucky College of Pharmacy.
"I am delighted to join the Relmada R&D team and look forward to advance REL-1017, an orally delivered anti-depressant with a potentially unique rapid-onset of action and sustained antidepressant effect for the treatment of patients with a major depressive disorder. REL-1071 has been designated by FDA as a Fast-Track drug, and, if approved, will fulfill an unmet medical need for patients with a serious condition," said Dr. Walter. "It is an exciting time for the Company, and I look forward to working with the Relmada team to develop regulatory strategies to advance this innovative treatment for patients and their families."
"Dr. Walter has an impressive track record in regulatory affairs. We are thrilled to have Brian join the growing Relmada R&D team at this juncture, as we plan for our phase 3 program of REL-1017 and consider regulatory strategies in the EU, Japan and the rest of the world," said Thomas Wessel, Head of Research and Development at Relmada.
"Brian is a highly experienced regulatory affairs professional," said Sergio Traversa, Chief Executive Officer of Relmada. "He has led the interactions with regulatory agencies globally around a multitude of development and marketed products. We look forward to leveraging Brian's broad expertise as we discuss the planning of our pivotal Phase 3 program of REL-1017 as an adjunctive treatment in patients with major depression with the U.S. Food and Drug Administration and other regulatory agencies around the world."
About dextromethadone (REL-1017)
Relmada is currently developing dextromethadone as a rapidly acting oral agent for the treatment of depression. Working as an NMDA receptor antagonist and on the same binding site as ketamine but having shown no ketamine psychotomimetics side effects, dextromethadone is fundamentally differentiated from all currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively. In April 2017, the FDA granted Fast Track designation for dextromethadone for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com
For Media Inquiries:
FischTank Marketing and PR
mailto://relmada@fischtankpr.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-enhances-senior-leadership-team-with-appointment-of-brian-a-walter-phd-as-vice-president-of-regulatory-affairs-301048136.html
SOURCE Relmada Therapeutics, Inc.
Thar she blows !
https://blog.tipranks.com/goldman-sachs-2-stocks-that-could-climb-over-60/
Russell 2000 ranking day is May 8, 2020. RLMD should get included...would result in some add'l share purchases in June by funds that track the Russell 2000.
And tomorrow is a new moon!
BTD? That would be interesting
Ahab the chartist:
Goldman Sachs issues buy report on RELMADA price target $64
My target still $500 in 3 years
RLMD will broach on the new moon in April
(23rd)
Seems to have east coast sellers in the morning and west coast buyers by early afternoon...every day
Informed speculation that REL 1017 could become the Standard of Care for TRD supports my estimates if $500-$1000/ share
20,000 buyer at the close bumped it up $1.25/ share hmmm
NEWS -- Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
NEW YORK, March 31, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety. Dr. de Somer will oversee Clinical Development and Safety at Relmada. He has over 30 years of experience in global clinical development strategy, design, execution, and evaluation.
Dr. de Somer joins Relmada from Prilenia Therapeutics, a privately-held, clinical-stage biotechnology company focused on developing treatments for neurodegenerative and neurodevelopmental disorders, where he served as Chief Medical Officer (CMO). He was responsible for clinical R&D strategy, tactical leadership and management from translational medicine to full development and regulatory interactions. Previously, Dr. de Somer served as VP of Clinical R&D & Medical Affairs at leading CNS-focused biotechnology companies, Voyager Therapeutics and Alkermes, and also was VP Neurology at PPD Biotech, a prominent clinical research organization. In these roles, he was responsible for numerous pre-IND to NDA interactions with U.S., European and Japanese regulators. During the course of his career, Dr. de Somer's clinical leadership has resulted in global regulatory approvals of several drugs, including Exelon® in Alzheimer's dementia, Comtan® and Stalevo® in Parkinson's disease, Differin® in dermatology, Artistada® in schizophrenia, and he is a co-inventor of apomorphine sublingual film (acquired by Sunovion and currently undergoing NDA review) in late-stage Parkinson's disease, as well as Miacalcin® in post-menopausal osteoporosis and Sandimmune® Neoral® in organ transplantation. Earlier in his career, Dr. de Somer co-founded three venture capital-backed clinical-stage neuroscience start-ups where he served as CMO and EVP R&D, with two successful mergers and acquisitions (M&A) exits. Prior to this, he had leadership responsibilities in Europe, UK and U.S. of clinical line functions and projects at Sandoz/Novartis Pharmaceuticals.
Dr. de Somer earned an MD from Brussels Free University, Belgium, a doctorate from the Institute of Tropical Medicine in Antwerp, Belgium, an MSc in biostatistics (a joint program of Harvard School of Public Health, Imperial College London, and Leuven/Hasselt University, Belgium), and an executive MBA from Columbia University Business School. Additionally, he has an MPH, a postgraduate degree in epidemiology and an MSc in pharmaceutical medicine.
"Marc has led the development of multiple marketed CNS drugs during his prominent career," said Thomas Wessel, Head of R&D at Relmada. "We are thrilled to have someone with his vast knowledge of the CNS field, extensive clinical trial management experience and substantial regulatory expertise join our team. We are now planning for our first pivotal Phase 3 study of REL-1017 as an adjunctive treatment in patients with major depression to start in the second half of this year, and Marc's contributions to study design and execution will be critical."
"I am very excited to focus on maximizing our probability of success, defeating placebo response and excessive noise to demonstrate the true therapeutic signal with the necessary accuracy, precision and replicability. I look forward to working with the Relmada team, as we effectively conduct clinical trials to provide the highest quality of information and therapeutic value for patients, prescribers, payers and shareholders." said Dr. de Somer. "I look forward to contributing to de-risking development of REL-1017 in MDD, and additional indications and programs, as we build our pipeline and team."
About dextromethadone (REL 1017)
Relmada is currently developing dextromethadone as a rapidly acting oral agent for the treatment of depression. Working as an NMDA receptor antagonist and on the same binding site as ketamine but having shown no ketamine psychotomimetics side effects, dextromethadone is fundamentally differentiated from all currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively. In April 2017, the FDA granted Fast Track designation for dextromethadone for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com
For Media Inquiries:
FischTank Marketing and PR
mailto://relmada@fischtankpr.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-solidifies-its-rd-leadership-team-with-the-appointment-of-marc-de-somer-md-mba-scd-mph-msc-as-senior-vice-president-clinical-development-and-safety-301032481.html
SOURCE Relmada Therapeutics, Inc.
Strange day, 5 up days MACD breakout ( lower right crossing) didn’t happen.
In sympathy w AXSM and SAGE ? No relation to RLMD
https://stockcharts.com/h-sc/ui?s=RLMD
NEWS -- Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
NEW YORK, March 24, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Judy Caron, Ph.D., as Vice President of Drug Development. Dr. Caron has 30 years of experience in biopharmaceutical development.
Dr. Caron joins Relmada from Neurana Pharmaceuticals, a privately-held, clinical stage, biopharmaceutical company focused on the treatment of neuromuscular conditions. Dr. Caron co-founded the company in 2012 and served as Chief Operating Officer (COO) and Head of Clinical Development. Her responsibilities included project management, clinical development, chemistry and pharmaceutical development, and regulatory operations. Previously, Dr. Caron was COO and a partner at BioNevia Pharmaceuticals, LLC, from 2008-2014. Prior to this, she served in increasingly senior drug development-related roles as Vice President CNS Program Director at Sepracor Inc from 1997-2008. At Sepracor, Dr. Caron directed several CNS projects, including the development and approval of Lunesta® in the U.S. and Japan. She began her career at Sandoz Pharmaceuticals where she was Project Coordination Manager. Dr. Caron holds a Ph.D. in molecular genetics from Emory University, an M.S. degree in genetics from Ohio State University and a B.S. degree in biology from Cleveland State University.
"Dr. Caron has extensive CNS drug development experience," said Thomas Wessel, Head of Research and Development at Relmada. "We are thrilled to add someone of Judy's caliber to our senior management team. Dr. Caron will be an instrumental team member to further advance REL-1017 in the clinic. This agent has the potential to become an important oral and rapid-acting adjunctive treatment in patients with major depression, and Judy will provide critical support to our team for the next steps in clinical development and the regulatory review process."
"I am delighted to join Relmada to continue the development of REL-1017, which could offer a compelling new treatment option to the millions of patients suffering from depression," said Dr. Caron. "REL-1017 has previously shown rapid, statistically and clinically meaningful antidepressant activity, in conjunction with a favorable tolerability and safety profile. I look forward to working with the Relmada team to further evaluate this promising drug candidate in late-stage clinical trials."
About dextromethadone (REL 1017)
Relmada is currently developing dextromethadone as a rapidly acting oral agent for the treatment of depression. Working as an NMDA receptor antagonist and on the same binding site as ketamine but having shown no ketamine psychotomimetics side effects, dextromethadone is fundamentally differentiated from all currently FDA-approved antidepressants, as well as all atypical antipsychotics used adjunctively. In April 2017, the FDA granted Fast Track designation for dextromethadone for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
mailto://tim@lifesciadvisors.com
For Media Inquiries:
FischTank Marketing and PR
mailto://relmada@fischtankpr.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/relmada-therapeutics-strengthens-scientific-leadership-team-with-the-appointment-of-judy-caron-phd-as-vice-president-of-drug-development-301028890.html
SOURCE Relmada Therapeutics, Inc.
Followers
|
22
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
513
|
Created
|
08/10/14
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |